黑色素瘤个体化新抗原疫苗的研究进展  

Advances in individualized neoantigen vaccines for treatment of melanoma

作　　者：干佳璇 邹征云[1,2] GAN Jiaxuan;ZOU Zhengyun(Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing 210008,China;The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China)

机构地区：[1]南京中医药大学中西医结合鼓楼临床医学院肿瘤科,南京210008 [2]南京大学医学院附属鼓楼医院肿瘤中心,南京210008

出　　处：《国际免疫学杂志》2024年第5期528-533,共6页International Journal of Immunology

基　　金：国家自然科学基金(82073365)。

摘　　要：生产有效的肿瘤疫苗来控制黑色素瘤是近些年新兴的治疗方法之一,随着第二代测序技术的发展,研发个体化新抗原(neoantigen)疫苗已成为肿瘤治疗性疫苗的未来发展方向。文章就用于治疗黑色素瘤的个体化新抗原疫苗的研究进展,使用治疗性疫苗的障碍以及克服这些障碍的有效策略进行概述。In recent years,the production of effective tumor vaccines to control melanoma has been one of the emerging therapeutic approaches.With the advancement of second-generation sequencing technology,there is now a focus on developing individualized neoantigen vaccines for personalized treatment.This review provides an overview of the progress of research on individualized neoantigen-based vaccines for the treatment of melanoma,the barriers to the use of therapeutic vaccines,and effective strategies to overcome these barriers.

关 键 词：黑色素瘤 治疗性疫苗 新抗原 个体化 

分 类 号：R739.5[医药卫生—肿瘤] R730.5[医药卫生—临床医学]